vs
Side-by-side financial comparison of Keros Therapeutics, Inc. (KROS) and SciSparc Ltd. (SPRC). Click either name above to swap in a different company.
SciSparc Ltd. is the larger business by last-quarter revenue ($461.0K vs $385.0K, roughly 1.2× Keros Therapeutics, Inc.). On growth, SciSparc Ltd. posted the faster year-over-year revenue change (-45.1% vs -87.3%).
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for hematological disorders, musculoskeletal diseases and anemia, serving underserved patient groups with unmet medical needs from its core U.S. base.
SciSparc Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs in the neurological, psychiatric, and gastrointestinal disorder segments. It operates across global biotech markets, leveraging proprietary cannabinoid-based formulation technologies to advance its pipeline of therapeutic candidates.
KROS vs SPRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $385.0K | $461.0K |
| Net Profit | — | $-9.4M |
| Gross Margin | — | 78.1% |
| Operating Margin | — | -588.5% |
| Net Margin | — | -2041.6% |
| Revenue YoY | -87.3% | -45.1% |
| Net Profit YoY | 49.0% | -155.8% |
| EPS (diluted) | — | $17.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $385.0K | — | ||
| Q3 25 | $14.3M | — | ||
| Q2 25 | $18.2M | $461.0K | ||
| Q1 25 | $211.2M | — | ||
| Q4 24 | — | $466.0K | ||
| Q3 24 | $388.0K | — | ||
| Q2 24 | $37.0K | $840.0K | ||
| Q1 24 | $83.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | $-7.3M | — | ||
| Q2 25 | $-30.7M | $-9.4M | ||
| Q1 25 | $148.5M | — | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | $-53.0M | — | ||
| Q2 24 | $-45.3M | $-3.7M | ||
| Q1 24 | $-43.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 78.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 56.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -107.9% | — | ||
| Q2 25 | -219.2% | -588.5% | ||
| Q1 25 | 72.0% | — | ||
| Q4 24 | — | -813.1% | ||
| Q3 24 | -15117.8% | — | ||
| Q2 24 | -136321.6% | -419.9% | ||
| Q1 24 | -58413.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | -51.0% | — | ||
| Q2 25 | -169.0% | -2041.6% | ||
| Q1 25 | 70.3% | — | ||
| Q4 24 | — | -813.9% | ||
| Q3 24 | -13648.5% | — | ||
| Q2 24 | -122316.2% | -438.0% | ||
| Q1 24 | -51944.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.18 | — | ||
| Q2 25 | $-0.76 | $17.92 | ||
| Q1 25 | $3.62 | — | ||
| Q4 24 | — | $-8.82 | ||
| Q3 24 | $-1.41 | — | ||
| Q2 24 | $-1.25 | $35.70 | ||
| Q1 24 | $-1.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $287.4M | $1.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $303.1M | $-81.0K |
| Total Assets | $338.0M | $5.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $287.4M | — | ||
| Q3 25 | $693.5M | — | ||
| Q2 25 | $690.2M | $1.5M | ||
| Q1 25 | $720.5M | — | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | $530.7M | — | ||
| Q2 24 | $405.9M | $252.0K | ||
| Q1 24 | $442.4M | — |
| Q4 25 | $303.1M | — | ||
| Q3 25 | $703.6M | — | ||
| Q2 25 | $706.7M | $-81.0K | ||
| Q1 25 | $728.9M | — | ||
| Q4 24 | — | $8.9M | ||
| Q3 24 | $532.8M | — | ||
| Q2 24 | $420.9M | $8.7M | ||
| Q1 24 | $453.9M | — |
| Q4 25 | $338.0M | — | ||
| Q3 25 | $742.8M | — | ||
| Q2 25 | $757.2M | $5.1M | ||
| Q1 25 | $784.6M | — | ||
| Q4 24 | — | $10.3M | ||
| Q3 24 | $579.3M | — | ||
| Q2 24 | $455.0M | $10.5M | ||
| Q1 24 | $485.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $107.5M | $-1.9M |
| Free Cash FlowOCF − Capex | $106.0M | — |
| FCF MarginFCF / Revenue | 27520.5% | — |
| Capex IntensityCapex / Revenue | 402.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $239.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $107.5M | — | ||
| Q3 25 | $3.2M | — | ||
| Q2 25 | $-29.6M | $-1.9M | ||
| Q1 25 | $161.2M | — | ||
| Q4 24 | — | $-2.9M | ||
| Q3 24 | $-30.5M | — | ||
| Q2 24 | $-39.8M | $-2.2M | ||
| Q1 24 | $-44.6M | — |
| Q4 25 | $106.0M | — | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | $-30.3M | — | ||
| Q1 25 | $160.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-30.9M | — | ||
| Q2 24 | $-40.1M | $-2.2M | ||
| Q1 24 | $-45.5M | — |
| Q4 25 | 27520.5% | — | ||
| Q3 25 | 21.9% | — | ||
| Q2 25 | -167.0% | — | ||
| Q1 25 | 76.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -7960.3% | — | ||
| Q2 24 | -108408.1% | -261.7% | ||
| Q1 24 | -54826.5% | — |
| Q4 25 | 402.9% | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 99.5% | — | ||
| Q2 24 | 837.8% | 0.1% | ||
| Q1 24 | 1139.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.09× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
